[1]
|
Tsao, C.W., Aday, A.W., Almarzooq, Z.I., et al. (2022) Heart Disease and Stroke Statistics-2022 Update: A Report from the American Heart Association. Circulation, 145, e153-e639.
|
[2]
|
中国心血管健康与疾病报告2021概要[J]. 中国循环杂志, 2022, 37(6): 553-578.
|
[3]
|
Furtado, R.H.M., Fagundes, A.A., Oyama, K., et al. (2022) Effect of Evo-locumab in Patients with Prior Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 15, e011382.
https://doi.org/10.1161/CIRCINTERVENTIONS.121.011382
|
[4]
|
张峰, 金琴花. 急性冠状动脉综合征患者血脂管理临床路径专家共识[J]. 中国循环杂志, 2020, 35(10): 941-947.
|
[5]
|
Koskinas, K.C., Siontis, G.C.M., Piccolo, R., et al. (2018) Effect of Statins and Non-Statin LDL-Lowering Medications on Cardiovascular Outcomes in Secondary Prevention: A Meta-Analysis of Randomized Trials. European Heart Journal, 39, 1172-1180. https://doi.org/10.1093/eurheartj/ehx566
|
[6]
|
Mach, F., Baigent, C., Catapano, A.L., et al. (2020) 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk. European Heart Journal, 41, 111-188.
https://doi.org/10.1093/eurheartj/ehz455
|
[7]
|
Chen, P.Y., Chien, K.L., Lin, Z.F., et al. (2017) Effectiveness of a Combination of Ezetimibe and Statins in Patients with Acute Coronary Syndrome and Multiple Comorbidities: A 6-Year Population-Based Cohort Study. International Journal of Cardiology, 233, 43-51. https://doi.org/10.1016/j.ijcard.2017.02.006
|
[8]
|
Sabatine, M.S., Giugliano, R.P., Keech, A.C., et al. (2017) Evo-locumab and Clinical Outcomes in Patients with Cardiovascular Disease. The New England Journal of Medicine, 376, 1713-1722. https://doi.org/10.1056/NEJMoa1615664
|
[9]
|
Navarese, E.P., Kołodziejczak, M., Petrescu, A., et al. (2018) Role of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients with Coronary Artery Disease Un-dergoing Percutaneous Coronary Intervention. Expert Review of Cardiovascular Therapy, 16, 419-429. https://doi.org/10.1080/14779072.2018.1474099
|
[10]
|
Grundy, S.M., Stone, N.J., Bailey, A.L., et al. (2019) 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/ APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 139, e1046-e1081. https://doi.org/10.1161/CIR.0000000000000699
|
[11]
|
超高危动脉粥样硬化性心血管疾病患者血脂管理中国专家共识[J]. 中华心血管病杂志, 2020(4): 280-286.
|
[12]
|
Sabatine, M.S., De Ferrari, G.M., Giugliano, R.P., et al. (2018) Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis from FOURIER. Circula-tion, 138, 756-766.
https://doi.org/10.1161/CIRCULATIONAHA.118.034309
|
[13]
|
Rampidis, G.P., Benetos, G., Benz, D.C., et al. (2019) A Guide for Gensini Score Calculation. Atherosclerosis, 287, 181-183. https://doi.org/10.1016/j.atherosclerosis.2019.05.012
|
[14]
|
Gong, Y., Li, X., Ma, X., et al. (2021) Lipid Goal At-tainment in Post-Acute Coronary Syndrome Patients in China: Results from the 6-Month Real-World Dyslipidemia In-ternational Study II. Clinical Cardiology, 44, 1575-1585.
https://doi.org/10.1002/clc.23725
|
[15]
|
Mangione, C.M., Barry, M.J., Nicholson, W.K., et al. (2022) Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. JAMA, 328, 746-753.
https://doi.org/10.1001/jama.2022.13044
|
[16]
|
Bayturan, O., Kapadia, S., Nicholls, S.J., et al. (2010) Clinical Pre-dictors of Plaque Progression despite Very Low Levels of Low-Density Lipoprotein Cholesterol. JACC: Journal of the American College of Cardiology, 55, 2736-2742.
https://doi.org/10.1016/j.jacc.2010.01.050
|
[17]
|
Nakamura, M., Ako, J., Arai, H., et al. (2021) Lipid Management and 2-Year Clinical Outcomes in Japanese Patients with Acute Coronary Syndrome: EXPLORE-J. Journal of Athero-sclerosis and Thrombosis, 28, 1307-1322.
https://doi.org/10.5551/jat.59543
|
[18]
|
Burgess, S., Ference, B.A., Staley, J.R., et al. (2018) Association of LPA Variants with Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Ran-domization Analysis. JAMA Cardiology, 3, 619-627. https://doi.org/10.1001/jamacardio.2018.1470
|
[19]
|
Tsimikas, S., Gordts, P., Nora, C., et al. (2020) Statin Therapy Increases Lipoprotein(a) Levels. European Heart Journal, 41, 2275-2284. https://doi.org/10.1093/eurheartj/ehz310
|
[20]
|
Cannon, C.P., Blazing, M.A., Giugliano, R.P., et al. (2015) Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. The New England Journal of Medicine, 372, 2387-2397. https://doi.org/10.1056/NEJMoa1410489
|
[21]
|
Gencer, B., Carballo, D. and Nanchen, D. (2020) Inten-sified Lipid Lowering Using Ezetimibe after Publication of the IMPROVE-IT Trial: A Contemporary Analysis from the SPUM-ACS Cohort. International Journal of Cardiology, 303, 8-13. https://doi.org/10.1016/j.ijcard.2019.12.011
|
[22]
|
Dias, C.S., Shaywitz, A.J., Wasserman, S.M., et al. (2012) Ef-fects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels: Results from 2 Randomized, Double-Blind, Place-bo-Controlled, Ascending-Dose Phase 1 Studies in Healthy Volunteers and Hypercholesterolemic Subjects on Statins. JACC: Journal of the American College of Cardiology, 60, 1888-1898. https://doi.org/10.1016/j.jacc.2012.08.986
|
[23]
|
Nicholls, S.J., Puri, R., Anderson, T., et al. (2016) Effect of Evo-locumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA, 316, 2373-2384.
https://doi.org/10.1001/jama.2016.16951
|
[24]
|
Benjamin, E.J., Blaha, M.J., Chiuve, S.E., et al. (2017) Heart Dis-ease and Stroke Statistics-2017 Update: A Report from the American Heart Association. Circulation, 135, e146-e603. https://doi.org/10.1161/CIR.0000000000000485
|
[25]
|
Vagnarelli, F., Taglieri, N., Ortolani, P., et al. (2015) Long-Term Outcomes and Causes of Death after Acute Coronary Syndrome in Patients in the Bologna, Italy Area. American Journal of Cardiology, 115, 171-177.
https://doi.org/10.1016/j.amjcard.2014.10.019
|
[26]
|
Giugliano, R.P., Pedersen, T.R., Park, J.G., et al. (2017) Clini-cal Efficacy and Safety of Achieving Very Low LDL-Cholesterol Concentrations with the PCSK9 Inhibitor Evolocumab: A Prespecified Secondary Analysis of the FOURIER Trial. The Lancet, 390, 1962-1971. https://doi.org/10.1016/S0140-6736(17)32290-0
|
[27]
|
O’Donoghue, M.L., Giugliano, R.P., Wiviott, S.D., et al. (2022) Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease. Circulation, 146, 1109-1119.
https://doi.org/10.1161/CIRCULATIONAHA.122.061620
|
[28]
|
Hagström, E., Steg, P.G., Szarek, M., et al. (2022) Apolipoprotein B, Residual Cardiovascular Risk after Acute Coronary Syndrome, and Effects of Alirocumab. Circulation, 146, 657-672.
https://doi.org/10.1161/CIRCULATIONAHA.121.057807
|
[29]
|
O’Donoghue, M.L., Fazio, S., Giugliano, R.P., et al. (2019) Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation, 139, 1483-1492. https://doi.org/10.1161/CIRCULATIONAHA.118.037184
|